Device Trial Radar · NCT06601166
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
283
Actual
Start
Aug 15, 2024
Primary completion
May 13, 2026
Study completion Dec 16, 2026
Sponsor
- Lead sponsor
- DexCom, Inc.Public (DXCM)
- Sponsor type
- Industry
- Collaborators
- Jaeb Center for Health Research; Scripps Research Digital Trial Center; Precision Data Health, Inc.
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-center study is a 26-week randomized controlled trial (RCT) in which adults (≥18 years) with type 2 diabetes (T2D) not using insulin and managed in a primary-care setting will be randomly assigned 1:1 to either use of real-time continuous glucose monitoring (CGM) or routine care (RC) plus interval blinded CGM wear.
Conditions
- Type 2 Diabetes
Interventions
CGMDevice
Continuous Glucose Monitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the benefit on glycemic control and safety from baseline to week 26 using CGM versus RC.Time frame: 26 weeks
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado, Anschutz Medical Campus, Department of Family Medicine, Primary Care Diabetes Lab
Aurora, Colorado
Tekton Research
Denver, Colorado
East Coast Institute for Research
Lake City, Florida
18 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.